Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: A phase I dose-finding study

Veterinary and Comparative Oncology

Volumn 10, Issue 3, 2012, Pages 174-183

  Robat, C ^a   London, C ^b   Bunting, L ^a   Mccartan, L ^a   Stingle, N ^b   Selting, K ^c   Kurzman, I ^a   Vail, D M ^a,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Canine; Chemotherapy; Mast cell tumors; Oncology; Tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; TOCERANIB; VINBLASTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; MALE; MASTOCYTOSIS; PHASE 1 CLINICAL TRIAL; SKIN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; FEMALE; INDOLES; MALE; MASTOCYTOSIS; PROTEIN-TYROSINE KINASES; PYRROLES; SKIN NEOPLASMS; VINBLASTINE;

CANIS FAMILIARIS;

EID: 84864859815     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00261.x     Document Type: Article

References (40)

1. Thamm DH and Vail DM. Mast cell tumors. In: Small Animal Clinical Oncology, 4th edn., SJ Withrow and DM Vail, eds., Philadelphia, PA, WB Saunders, 2001: 402-424.
2. Patnaik AK, Ehler WJ and MacEwen EG. Canine cutaneous mast cell tumors: morphologic grading and survival time in 83 dogs. Veterinary Pathology 1984; 21: 469-474.
3. Thamm DH, Mauldin EA and Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor - 41 cases (1992-1997). Journal of Veterinary Internal Medicine 1999; 13: 491-497.
4. Thamm DH, Turek MM and Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Journal of Veterinary Medical Science 2006; 68: 581-587.
5. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. Journal of Small Animal Practice 1973; 14: 27-41.
6. Hottendorf GH and Nielsen SW. Pathologic survey of 300 extirpated canine mastocytomas. Zentralblatt für Veterinärmedizin. Reihe A 1967; 14: 272-281.
7. Murphy S, Sparkes AH, Smith KC, Blunden AS and Brearley MJ. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Veterinary Record 2004; 154: 743-746.
8. Turrel JM, Kitchell BE, Miller LM and Iheon A. Prognostic factors for radiation treatment of mast cell tumour in 85 dogs. Journal of the American Veterinary Medical Association 1988; 193: 936-940.
9. Ayl RD, Couto CG, Hammer AS, Weisbrode S, Ericson JG and Mathes L. Correlation of DNA ploidy to tumour histologic grade, clinical variables, and survival in dogs with mast cell tumours. Veterinary Pathology 1992; 29: 386-390.
10. Gieger TL, Théon AP, Werner JA, McEntee MC, Rassnick KM and DeCock HE. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001). Journal of Veterinary Internal Medicine 2003; 17: 687-692.
11. Simoes JP, Schoning P and Butine M. Prognosis of canine mast cell tumors: a comparison of three methods. Veterinary Pathology 1994; 31: 637-647.
12. McCaw DL, Miller MA, Bergman PJ, Withrow SJ, Moore AS, Knapp DW, Fowler D and Johnson JC. Vincristine therapy for mast cell tumors in dogs. Journal of Veterinary Internal Medicine 1997; 11: 375-378.
13. Davies DR, Wyatt KM, Jardine JE, Robertson ID and Irwin PJ. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumours. Journal of the American Animal Hospital Association 2004; 40: 124-130.
14. Vickery KR, Wilson H, Vail DM and Thamm DH. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Veterinary and Comparative Oncology 2007; 6: 111-119.
15. Bailey DB, Rassnick KM, Kristal O, Chretin JD and Balkman CE. Phase I dose escalation of single agent vinblastine in dogs. Journal of Veterinary Internal Medicine 2008; 22: 1397-1402.
16. Rassnick KM, Bailey DB, Flory AB, Balkman CE, Kiselow MA, Intile JL and Autio K. Efficacy of vinblastine for treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008; 22: 1390-1396.
17. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G and Cherrington JM. Phase I dose escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 2003; 9: 2755-2768.
18. London CA. Kinase inhibitors in cancer therapy. Veterinary and Comparative Oncology 2004; 2: 177-193.
19. Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM and London CA. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clinical Cancer Research 2003; 9: 5729-5734.
20. London CA, Malpais PB, Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN and Michels GM. Multicenter, placebo-controlled, double-blind, randomized study of oral Palladia (SU11654) in the treatment of dogs with recurrent mast cell tumors. Clinical Cancer Research 2009; 15: 3856-3865.
21. Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A and Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of the American Veterinary Medical Association 2008; 22: 1301-1309.
22. Rassnick KM, Al-Sarraf R, Bailey DB, Chretin JD, Phillips B and Zwhalen CH. Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs. Veterinary and Comparative Oncology 2010; 8: 103-111.
23. Rassnick KM, Moore AS, Williams LE, London CA, Kintzer PP, Engler SJ and Cotter SM. Treatment of canine mast cell tumors with CCNU (lomustine). Journal of Veterinary Internal Medicine 1999; 13: 601-605.
24. Gerritsen RJ, Teske E, Kraus JS and Rutteman GR. Multi-agent chemotherapy for mast cell tumors in the dog. Veterinary Questions 1998; 20: 28-31.
25. Trumel C, Bourges-Abella N, Touron C, Lanore D, Geffré A, Diquelou A, Guelfi JF and Braun JP. Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours. Journal of Veterinary Medicine A, Physiology, Pathology, Clinical Medicine 2005; 52: 275-279.
26. Camps-Palau MA, Leibman NF, Elmslie R, Lana SE, Plaza S, McKnight JA, Risbon R and Bergman PJ. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Veterinary and Comparative Oncology 2007; 5: 156-167.
27. DeVita VT. Principles of cancer management: chemotherapy. In: Cancer: Principles and Practice of Oncology, 7th edn., HSVT DeVita and SA Rosenberg, eds., Philadelphia, PA, Lippincott-Raven Publishers, 2005: 298-300.
28. Vail DM. Cancer clinical trials: development and implementation. Veterinary Clinics of North America: Small Animal Practice 2007; 37: 1033-1057.
29. Veterinary Co-operative Oncology Group (VCOG). Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004; 2: 195-213.
30. Scagliotti G, Rossi A and Novello S. Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2004; 22: 7081.
31. Davies AM, Ho C, Hesketh PJ, Beckett LA, Lara PN Jr, Lau D and Gandara DR. Erlotinib and vinorelbine in advances malignant solid tumors: a phase I study. Investigational New Drugs 2007; 25: 351-355.
32. Pujol JL, Viens P, Rebattu P, Laurie SA, Feld R, Deneulin A and Fandi A. Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. Journal of Thoracic Oncology 2006; 1: 417-424.
33. Sanoff HK, Davies J, Walko C, Irvin W, Buie W and Keller K. A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors. Investigational New Drugs 2010; doi: 10.1007/s10637-010-9427-1.
34. Kajita J, Kuwabara T, Kobayashi H and Kobayashi S. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metabolism and Disposition 2000; 28: 1121-1127.
35. Yancey MF, Merritt DA, White JA, Marsh SA and Locuson CW. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs. Journal of Veterinary Pharmacology and Therapeutics 2010; 33: 154-161.
36. Wang XK and Fu LW. Interaction of tyrosine kinase inhibitors with the MDR-related ABC transporter proteins. Current Drug Metabolism 2010; 11: 618-628.
37. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ and Fu LW. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Letters 2009; 279: 74-83.
38. Shukla S, Robey RW, Bates SE and Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition 2009; 37: 359-365.
39. Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, Boudriot U and Neubauer A. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007; 2: 1267-1275.
40. Henry CJ, Downing S, Rosenthal RC, Klein MK, Meleo K, Villamil JA, Fineman LS, McCaw DL, Higginbotham ML and McMichael J. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. American Journal of Veterinary Research 2007; 68: 1246-1251.